Company Description
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The company’s lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer’s Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors.
The company was founded in 2017 and is headquartered in Bethesda, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Gene Mack |
Contact Details
Address: 4800 Montgomery Lane, Suite 220 Bethesda, Maryland 20814 United States | |
| Phone | 301 500 1556 |
| Website | gaintherapeutics.com |
Stock Details
| Ticker Symbol | GANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001819411 |
| CUSIP Number | 36269B105 |
| ISIN Number | US36269B1052 |
| Employer ID | 85-1726310 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gene Mack | Chief Executive Officer |
| Gene Mack | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Sep 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 6, 2024 | 424B5 | Filing |
| Sep 6, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |